v3.26.1
Financial assets and liabilities - Summary of Changes in the Contingent Consideration Fair Value of Level 3 Instruments (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Jan. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2023
Disclosure Of Financial Instruments [Line Items]          
Remeasurement   $ (4,165) $ 4,625 $ 9,693  
Proceeds from issue of shares   $ 2,602 161,205 $ 65,406  
Remeasurement of contingent consideration, milestone payment     $ 10,300    
Ordinary shares          
Disclosure Of Financial Instruments [Line Items]          
Ordinary shares (in shares)   1,296,862,776 1,279,967,187 1,141,784,114 814,204,825
Ordinary shares | Osiris Therapeutics, Inc.          
Disclosure Of Financial Instruments [Line Items]          
Ordinary shares (in shares) 10,228,239        
Proceeds from issue of shares $ 20,000        
Level 3          
Disclosure Of Financial Instruments [Line Items]          
Opening balance   $ 21,779 $ 26,892    
Amount paid during the period   (2,370) (20,000)    
Remeasurement   (12,057) 14,887    
Closing balance   $ 7,352 $ 21,779 $ 26,892  
Expected term   12 months 12 months    
Remeasurement of contingent consideration, changes in key assumptions   $ 4,200 $ 4,600    
Remeasurement of contingent consideration, milestone payment   $ 7,900